An invitation to Europe's largest forum on breast cancer

January 25, 2012

What is EBCC?

The most exciting breast cancer conference in Europe, it is the only one that involves all the major players in breast cancer. The conference encourages interaction and collaboration between clinicians, scientists and patients in a partnership of equals to talk not just about scientific advances, but also the ethical, social, political, and practical issues associated with caring for patients with breast cancer. EBCC-8 is expected to attract over 5000 delegates from around 90 countries worldwide.

The conference covers the entire spectrum of breast cancer and highlights what is new across fields as diverse as:To find details of the programme:

Visit the EBCC-8 web site: http://www.ecco-org.eu/Conferences/Conferences/EBCC.aspx

Free media registration - on provision of bona fide press credentials

We welcome the media to EBCC-8. All sessions are open to journalists and registration is free to bona fide journalists on presentation of official press credentials. A media centre with computers, fax, printing, photocopying and free local and international telephone facilities and internet connections will be available. NB: the official conference language is English.

To register now: Register on the web site: http://www.ecco-org.eu/Conferences/Conferences/EBCC/Media/Registration-for-Press.aspx

If you wish to book accommodation, booking agents details can be found on: http://www.ecco-org.eu/Conferences/Conferences/EBCC/Accommodation.aspx
-end-


ECCO-the European CanCer Organisation

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.